ROR

Cat. No.

A77556

CAS No.

1873358-87-2

XY018

XY018 is a selective antagonist of ROR-γ (retinoic acid receptor-related orphan receptor gamma), designed to inhibit its constitutive activity. With an EC50 value of 190 nM in 293T cells, XY018 effectively disrupts ROR-γ signaling by binding to its hydrophobic ligand binding domain. This compound is valuable for research applications focused on autoimmune diseases, metabolic disorders, and inflammation by modulating ROR-γ activity.

Cat. No.

A77557

CAS No.

1817773-66-2

Bevurogant

Synonyms: BI 730357

Bevurogant is a selective antagonist of the retinoid-related orphan receptor gamma t (RORγt), which plays a critical role in immune response and inflammation. This compound is primarily utilized in research focused on chronic inflammatory diseases, offering insights into therapeutic strategies for conditions such as autoimmune disorders. Its ability to modulate RORγt activity makes it a valuable tool in the study of immune regulation and potential treatment pathways.

Cat. No.

A77565

CAS No.

1334526-14-5

(±)-ML 209

(±)-ML 209 is a selective RORγ antagonist that effectively inhibits RORγt transcriptional activity, demonstrating an IC50 of 300 nM in HEK293t cells. This diphenylpropanamide compound specifically suppresses murine Th17 cell differentiation while leaving the differentiation of naïve CD4+ T cells into Th1 and regulatory T cell lineages unaffected. Its unique mechanism makes (±)-ML 209 a valuable tool for researchers investigating the role of RORγ in immune responses and related diseases.

Cat. No.

A77568

CAS No.

1421837-45-7

TMP920

TMP920 is a potent and selective antagonist of RORγt, a retinoic acid receptor-related orphan receptor involved in immune signaling. It effectively inhibits the binding of RORγt to the SRC1 peptide, demonstrating an IC50 value of 0.03 μM. TMP920 is valuable for research applications focusing on autoimmune diseases, as well as the modulation of Th17 cell differentiation and function.

Cat. No.

A77569

CAS No.

1537859-24-7

GNE-3500

GNE-3500 is a selective, orally active antagonist of Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as RORγ or NR1F3), exhibiting an EC50 of 12 nM. This compound demonstrates favorable pharmacokinetic properties in rat models, making it a valuable tool for research applications focused on modulating RORc-related pathways. GNE-3500 is particularly relevant for studies investigating autoimmune diseases and inflammatory responses where RORc plays a critical regulatory role.

Cat. No.

A77579

CAS No.

1950570-48-5

Retezorogant

Retezorogant is a selective antagonist of the retinoid-related orphan receptor gamma (RORγ). This compound plays a significant role in modulating immune responses and has potential applications in the treatment of autoimmune diseases and inflammatory conditions. Retezorogant's ability to inhibit RORγ activity makes it a valuable tool for researchers investigating the mechanisms of Th17 cell differentiation and related pathways.

Cat. No.

A77590

CAS No.

3049676-15-2

RORγ antagonist 1

RORγ antagonist 1 is a potent antagonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) with a dissociation constant (KD) of 0.18 μM. This compound demonstrates significant anti-proliferative effects in HPAF-II pancreatic cancer xenograft models. Additionally, RORγ antagonist 1 inhibits key signaling pathways, including RAS/MAPK and AKT/mTORC1, and induces caspase-dependent apoptosis in pancreatic cancer cells, making it a valuable tool for cancer research and potential therapeutic applications.